INT168262

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 10.72
Pain Relevance 0.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (BPHL) cellular amino acid metabolic process (BPHL)
Anatomy Link Frequency
Th17 cells 2
bladder 2
BPHL (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 12 97.86 Very High Very High Very High
antagonist 24 96.32 Very High Very High Very High
cytokine 1 94.20 High High
withdrawal 16 90.96 High High
Onset of action 9 89.96 High High
pain pelvic 1 89.24 High High
Prostatitis 5 88.44 High High
Central nervous system 6 87.96 High High
Botox 56 68.56 Quite High
agonist 2 56.56 Quite High
Disease Link Frequency Relevance Heat
Benign Prostatic Hypertrophy 842 100.00 Very High Very High Very High
Overactive Bladder 212 100.00 Very High Very High Very High
Apoptosis 10 100.00 Very High Very High Very High
INFLAMMATION 12 97.86 Very High Very High Very High
Urinary Tract Infection 18 96.64 Very High Very High Very High
Incontinence 12 94.56 High High
Diuresis 61 93.36 High High
Renal Insufficiency 17 92.80 High High
Lower Urinary Tract Symptoms 221 91.24 High High
Chronic Pelvic Pain Syndrome 1 89.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
-reductase reduces the clinical progression of BPH, an effect that is further enhanced by the addition of an ?
Positive_regulation (enhanced) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
1) Confidence 0.24 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684085 Disease Relevance 1.08 Pain Relevance 0.08
Unlike prior studies, BPH progression was used as the primary endpoint, defined as an increase above baseline of at least 4 points in the American Urological Association symptom score, socially unacceptable urinary incontinence, a 50% increase in creatinine relative to baseline values, acute urinary retention, or two or more urinary tract infections within 1 year (or a single episode of urosepsis due to bladder outlet obstruction).
Positive_regulation (increase) of Gene_expression (progression) of BPH in bladder associated with benign prostatic hypertrophy, overactive bladder and urinary tract infection
2) Confidence 0.22 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710385 Disease Relevance 0.66 Pain Relevance 0
The Combination of AvodartĀ® and Tamsulosin (CombAT) study is currently evaluating the combination of dutasteride with tamsulosin over 4 years in a population of men at increased risk of BPH progression.
Positive_regulation (increased) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
3) Confidence 0.22 Published 2008 Journal International Journal of Clinical Practice Section Abstract Doc Link PMC2440415 Disease Relevance 1.27 Pain Relevance 0
Effects on AUR and BPH-related surgery
Positive_regulation (on) of Gene_expression (surgery) of BPH-related associated with benign prostatic hypertrophy and overactive bladder
4) Confidence 0.22 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.71 Pain Relevance 0
Effects on AUR and BPH-related surgery
Positive_regulation (on) of Gene_expression (surgery) of BPH-related associated with benign prostatic hypertrophy and overactive bladder
5) Confidence 0.22 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.88 Pain Relevance 0.09
62 years at baseline had a significantly increased risk of overall clinical progression of BPH (20).
Positive_regulation (increased) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
6) Confidence 0.22 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.75 Pain Relevance 0
1-blocker monotherapy (Lepor et al 1996; Debruyne et al 1998; Kirby et al 2003), a 5-year study of combination therapy with doxazosin and finasteride demonstrated a significantly reduced risk of overall BPH progression (ie, increase in AUA Symptom Index of ?
Positive_regulation (increase) of Gene_expression (progression) of BPH associated with benign prostatic hypertrophy
7) Confidence 0.19 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 1.39 Pain Relevance 0.04
Cardillo et al. found elevated BCL2 expression in apoptosis resistant BPH following androgen deprivation [54].
Positive_regulation (elevated) of Gene_expression (expression) of BPH associated with benign prostatic hypertrophy and apoptosis
8) Confidence 0.13 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793011 Disease Relevance 1.12 Pain Relevance 0.09
FGF2, SMOC1 and TIMP2 were chosen for IHC testing, as these genes had markedly increased RNA expression levels in BPH relative to controls, and antibodies were available that produced specific and satisfactory staining of human TZ tissues.
Positive_regulation (increased) of Gene_expression (expression) of BPH associated with benign prostatic hypertrophy
9) Confidence 0.13 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793011 Disease Relevance 1.08 Pain Relevance 0
The autoimmune pathogenesis of CP/CPPS and the chronic inflammation characteristic of BPH will be reviewed within the context of the recent demonstration that human prostate stromal cells from BPH tissue can act as antigen-presenting cells and are not only able to activate CD4(+) T lymphocytes, but can also produce IL-12 and IL-23, which are key cytokines for the induction of pathogenic Th1 and Th17 cells.
Positive_regulation (stromal cells) of Gene_expression (tissue) of BPH in Th17 cells associated with benign prostatic hypertrophy, inflammation and cytokine
10) Confidence 0.13 Published 2009 Journal Expert Rev Clin Immunol Section Abstract Doc Link 20477643 Disease Relevance 1.21 Pain Relevance 0.39
The dynamic component of BPH is mediated mainly via ?
Positive_regulation (mediated) of Gene_expression (component) of BPH associated with benign prostatic hypertrophy
11) Confidence 0.06 Published 2006 Journal Yonsei Medical Journal Section Body Doc Link PMC2687757 Disease Relevance 0.56 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox